Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
khiriox
- Development stage
- Unknown
- Lead developer
- Khiron Life Sciences
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
KHIRIOX is a full-spectrum medical cannabis extract developed by Khiron Life Sciences. The KHIRIOX 12/14 formulation contains approximately 12 mg/ml of tetrahydrocannabinol (THC) and 14 mg/ml of cannabidiol (CBD) in a medium-chain triglyceride (MCT) carrier oil. [5-2, 3] It is derived from hybrid cannabis genetics, combining properties of different strains, and is produced using CO2 extraction. [5-1, 2, 7] The active ingredients, THC and CBD, act on the body's endocannabinoid system. KHIRIOX is primarily used for the management of chronic pain and has been shown to effectively reduce pain perception in a study of 2,112 patients. [1-9, 9] It is available as an unlicensed medication in several countries, including the UK, Germany, Colombia, Peru, and Brazil. [1-2, 4]
- Brand names
- KHIRIOX
- Other names
- KHIRIOX 12/14
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on khiriox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on khiriox.